Cipla’s Voluntary Recall: Ensuring Safety in Pharmaceuticals

Cipla USA, a subsidiary of the Indian drugmaker, is recalling over 400 cartons of generic anti-cancer drug Nilotinib due to a manufacturing issue. The recall is classified as Class III by the USFDA, indicating it is unlikely to cause adverse health effects. India plays a vital role in supplying US pharmaceuticals.

In a critical move to uphold safety standards, Cipla USA, a US-based arm of the Indian pharmaceutical company, is recalling more than 400 cartons of generic anti-cancer medication due to a manufacturing problem, stated the US Food and Drug Administration (USFDA).

The recall involves Nilotinib Capsules in two different strengths, 150 mg and 200 mg, following failed tablet or capsule specifications. Launched on February 18, this Class III voluntary recall highlights the company's commitment to quality, while also noting that such violations are unlikely to result in health risks according to the USFDA.

Remarkably, India maintains the highest number of USFDA-compliant pharma plants outside the United States, with Indian companies supplying a significant share of the US market--four out of ten prescriptions filled in the US were sourced from India in 2022.

(With inputs from agencies.)